Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia

Drug News and Perspectives

Volumn 21, Issue 6, 2008, Pages 323-330

  Lopez, Dayami ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN E RECEPTOR 2; ARGININE; ATORVASTATIN; BERBERINE; CHENODEOXYCHOLIC ACID; EPIDERMAL GROWTH FACTOR LIKE REPEAT A; FENOFIBRATE; GENE PRODUCT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; PEPTIDES AND PROTEINS; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PRAVASTATIN; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; PROTEINASE INHIBITOR; SIMVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; UNCLASSIFIED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; COMBINATION CHEMOTHERAPY; CREATINE KINASE BLOOD LEVEL; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE LOCATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC LINKAGE; GENETIC VARIABILITY; GLYCOSYLATION; HEPATIC TRANSAMINASE BLOOD LEVEL; HOMEOSTASIS AND REGULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPOCHOLESTEROLEMIA; LIGAND BINDING; MONOTHERAPY; MYOPATHY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN ENGINEERING; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RISK REDUCTION; SIDE EFFECT; UPREGULATION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HYPERCHOLESTEROLEMIA; LIVER; MICE; PROTEIN CONFORMATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, LDL; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS;

EID: 56249083919     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2008.21.6.1246795     Document Type: Article

References (84)

1. Benjannet, S., Rhainds, D., Essalmani, R. et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 2004, 279(47): 48865-75.
2. Maxwell, K.N., Breslow, J.L. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A 2004, 101(18): 7100-5.
3. Seidah, N.G., Benjannet, S., Wickham, L. et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 2003, 100(3): 928-33.
4. Timms, K.M., Wagner, S., Samuels, M.E. et al. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet 2004, 114(4): 349-53.
5. Abifadel, M., Varret, M., Rabes, J.P. et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003, 34(2): 154-6.
6. Allard, D., Amsellem, S., Abifadel, M. et al. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum Mutat 2005, 26(5): 497.
7. Cunningham, D., Danley, D.E., Geoghegan, K.F. et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol 2007, 14(5): 413-9.
8. Piper, D.E., Jackson, S., Liu, Q. et al. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure 2007, 15(5): 545-52.
9. Zhao, Z., Tuakli-Wosornu, Y., Lagace, T.A. et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006, 79(3): 514-23.
10. Lagace, T.A., Curtis, D.E., Garuti, R. et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in liver of parabiotic mice. J Clin Invest 2006, 116(11): 2995-3005.
11. Homer, V.M., Marais, A.D., Charlton, F. et al. Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa. Atherosclerosis 2008, 196(2): 659-66.
12. Cameron, J., Holla, O.L., Ranheim, T., Kulseth, M.A., Berge, K.E. and Leren, T.P. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum Mol Genet 2006, 15(9): 155128.
13. Nassoury, N., Blasiole, D.A., Tebon Oler, A. et al. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic 2007, 8(6): 718-32.
14. Chen, S.N., Ballantyne, C.M., Gotto, A.M., Tan, Y., Willerson, J.T. and Marian, A.J. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol 2005, 45(10): 1611-9.
15. Evans, D. and Beil, F.U. The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in women. BMC Med Genet 2006, 7: 66.
16. Abboud, S., Karhunen, P.J., Lutjohann, D. et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gene Is a Risk Factor of Large-Vessel Atherosclerosis Stroke. PLoS ONE 2007, 2(10): e1043.
17. Scartezini, M., Hubbart, C., Whittall, R.A., Cooper, J.A., Neil, A.H. and Humphries, S.E. The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men. Clin Sci (Lond) 2007, 113(11): 435-41.
18. Hallman, D.M., Srinivasan, S.R., Chen, W., Boerwinkle, E. and Berenson, G.S. Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood (from The Bogalusa Heart Study). Am J Cardiol 2007, 100(1): 69-72.
19. Cohen, J.C., Boerwinkle, E., Mosley, T.H. and Hobbs, H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006, 354(12): 1264-72.
20. Cohen, J., Pertsemlidis, A., Kotowski, I.K., Graham, R., Garcia, C.K. and Hobbs, H.H. Low LDL cholesterol in individuals of African descent resulting from frequent non-sense mutations in PCSK9. Nat Genet 2005, 37(2): 161-5.
21. Miyake, Y., Kimura, R., Kokubo, Y., Okayama, A., Tomoike, H., Yamamura, T. and Miyata, T. Genetic variants in PCSK9 in the Japanese population: rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population. Atherosclerosis 2008, 196(1): 29-36.
22. Cameron, J., Holla, O.L., Laerdahl, J.K. et al. Characterization of novel mutations in the catalytic domain of the PCSK9 gene. J Intern Med 2008, 263(4): 420-31.
23. Kwon, H.J., Lagace, T.A., McNutt, M.C., Horton, J.D. and Deisenhofer, J. Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci U S A 2008, 105(6): 1820-5.
24. Berge, K.E., Ose, L. and Leren, T.P. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler Thromb Vasc Biol 2006, 26(5): 1094-100.
25. Fasano, T., Cefalù, A.B., Di Leo, E. et al. A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol. Arterioscler Thromb Vasc Biol 2007, 27(3): 677-91.
26. Kotowski, I.K., Pertsemlidis, A., Luke, A., Cooper, R.S., Vega, G.L., Cohen, J.C. and Hobbs, H.H. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet 2006, 78(3): 410-22.
27. Lambert, G. Unravelling the functional significance of PCSK9. Curr Opin Lipidol 2007, 18(3): 304-9.
28. Bourbon, M., Alves, A.C., Medeiros, A.M., Silva, S. and Soutar, A.K. Investigators of Portuguese FH Study. Familial hypercholesterolaemia in Portugal. Atherosclerosis 2008, 196(2): 633-42.
29. Hooper, A.J., Marais, A.D., Tanyanyiwa, D.M. and Burnett, JR. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 2007, 193(2): 445-8.
30. Jain, S.C., Shinde, U., Li, Y., Inouye, M., H.M. and Berman, H.M. The crystal structure of an autoprocessed Ser221Cys-subtilisin E-propeptide complex at 2.0 A resolution. J Mol Biol 1998, 284(1): 137-44.
31. Hampton, E.N., Knuth, M.W., Li, J., Harris, J.L., Lesley, S.A. and Spraggon, G. The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain. Proc Natl Acad Sci USA 2007, 104(37): 14604-9.
32. Grozdanov, P.N., Petkov, P.M., Karagyozov, L.K. and Dabeva, M.D. Expression and localization of PCSK9 in rat hepatic cells. Biochem Cell Biol 2006, 84(1): 80-92.
33. Naureckiene, S., Ma, L., Sreekumar, K. et al. Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch Biochem Biophys 2003, 420(1): 55-67.
34. Bergeron, F., Leduc, R. and Day, R. Subtilase-like pro-protein convertases: from molecular specificity to therapeutic applications. J Mol Endocrinol 2000, 24(1): 1-22.
35. Mayne, J., Raymond, A., Chaplin, A. et al. Plasma PCSK9 levels correlate with cholesterol in men but not in women. Biochem Biophys Res Commun 2007, 361(2): 451-6.
36. Lambert, G., Ancellin, N., Charlton, F. et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem 2008, 54(6): 1038-45.
37. Alborn, W.E., Cao, G., Careskey, H.E. et al. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem 2007, 53(10): 1814-9.
38. Benjannet, S., Rhainds, D., Hamelin, J., Nassoury, N. and Seidah, N.G. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A. Functional consequences of natural mutations and post-translational modifications. J Biol Chem 2006, 281(41): 30561-72.
39. Dewpura, T., Raymond, A., Hamelin, J., Seidah, N.G., Mbikay, M., Chrétien, M. and Mayne, J. PCSK9 is phosphorylated by a Golgi casein kinase-like kinase ex vivo and circulates as a phosphoprotein in humans. FEBS J 2008, 275(13): 3480-93.
40. Schmidt, R.J., Zhang, Y., Zhao, Y. et al. A novel splicing variant of proprotein convertase subtilisin/kexin type 9. DNA Cell Biol 2008, 27(4): 183-9.
41. Humphries, S.E., Whittall, R.A., Hubbart, C.S. et al. Genetic causes of familial hypercholesterolaemia in UK patients: relation to plasma lipid levels and coronary heart disease risk. J Med Genet 2006, 43(12): 943-9.
42. Seidah, N.G., Mayer, G., Zaid, A. et al. The activation and physiological functions of the proprotein convertases. Int J Biochem Cell Biol 2008, 40(6-7): 1111-25.
43. Maxwell, K.N., Soccio, R.E., Duncan, E.M., Sehayek, E. and Breslow, J.L. Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J Lipid Res 2003, 44(11): 2109-19.
44. Jeong, H.J., Lee, H.S., Kim, K.S., Kim, Y.K., Yoon, D. and Park, S.W. Sterol-dependent regulation of proprotein convertase sublilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J Lipid Res 2008, 49(2): 399-409.
45. Costet, P., Cariou, B., Lambert, G. et al. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem 2006, 281(10): 6211-6218.
46. Horton, J.D., Shah, N.A., Warrington, J.A., Anderson, N.N., Park, S.W., Brown, M.S. and Goldstein, J.L. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci U S A 2003, 100(21): 12027-32.
47. Schmidt, R.J., Ficorilli, J.V., Zhang, Y. et al. A 15-ketosterol is a liver X receptor ligand that suppresses sterol-responsive element binding protein-2 activity. J Lipid Res 2006, 47(5): 1037-44.
48. Dubuc, G., Chamberland, A., Wassef, H., Davignon, J., Seidah, N.G., Bernier, L. and Prat, A. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2004, 24(8): 1454-9.
49. Careskey, H.E., Davis, R.A., Alborn, W.E., Troutt, J.S., Cao, G. and Konrad, R.J. Atorvastatin increases human serum levels of proprotein convertase subtilisin kexin type 9 (PCSK9). J Lipid Res 2008, 49(2): 394-8.
50. Bedi, M., Niesen, M. and Lopez, D. Inhibition of squalene synthase upregulates PCSK9 expression in rat liver. Arch Biochem Biophys 2008, 470(2): 116-9.
51. Gouni-Berthold, L, Berthold, H.K., Gylling, H. et al. Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men. Atherosclerosis 2008, 198(1): 198-207.
52. Kourimate, S., Le May, C., Langhi, C. et al. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9. J Biol Chem 2008, 283(15): 9666-73.
53. Nilsson, L.M., Abrahamsson, A., Sahlin, S., Gustafsson, U., Angelin, B., Parini, P. and Einarsson, C. Bile acids and lipoprotein metabolism: effects of cholestyramine and chenodeoxycholic acid on human hepatic mRNA expression. Biochem Biophys Res Commun 2007, 357(3): 707-711.
54. Niesen, M., Bedi, M. and Lopez, D. Diabetes alters LDL receptor and PCSK9 expression in rat liver. Arch Biochem Biophys 2008, 470(2): 111-5.
55. Lambert, G., Jarnoux, A.L., Pineau, T. et al. Fasting induces hyperlipidemia in mice overexpressing PCSK9: Lack of modulation of VLDL hepatic output by the LDLr. Endocrinology 2006, 147(10): 4985-4995.
56. Langhi, C., Le May, C., Kourimate, S. et al. Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes. FEBS Lett 2008, 582(6): 949-55.
57. Cameron, J., Ranheim, T., Kulseth, M.A., Leren, T.P. and Berge, K.E. Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis 2008, in press.
58. Qian, Y.W., Schmidt, R.J., Zhang, Y. et al. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res 2007, 48(7): 1488-98.
59. Zhang, D.W., Lagace, T.A., Garuti, R. et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007, 282(25): 18602-12.
60. Poirier, S., Mayer, G., Benjannet, S. et al. The proprotein convertase PCSK9 induces the degradation qf LDLR and its closest family members VLDLR and APOER2. J Biol Chem 2008, 283(4): 2363-72.
61. Grefhorst, A., McNutt, M.C., Lagace, T.A. and Horton, J.D. Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J Lipid Res 2008, 49(6): 1303-11.
62. Schmidt, R.J., Beyer, T.P., Bensch, W.R. et al. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo. Biochem Biophys Res Commun 2008, 370(4): 634-40.
63. McNutt, M.C., Lagace, T.A. and Horton, J.D. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J Biol Chem 2007, 282(29): 20799-803.
64. Li, J., Tumanut, C., Gavigan, J.A. et al. Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity. Biochem J 2007, 406(2): 203-7.
65. Fan, D., Yancey, P.G., Qiu, S., Ding, L., Weeber, E.J., Linton, M.F. and Fazio, S. Self-association of human PCSK9 correlates with its LDLR-degrading activity. Biochemistry 2008, 47(6): 1631-9.
66. Holla, O.L., Cameron, J., Berge, K.E., Ranheim, T. and Leren, T.P. Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly. BMC Cell Biol 2007, 8: 9.
67. Anderson, R.G.W., Brown, M.S. and Goldstein, J. L. Role of the coated endocytic vesicle in the uptake of receptor-bound low density lipoprotein in human fibroblasts. Cell 1977, 10(3): 351-64.
68. Riddell, D.R., Sun, X.M., Stannard, A.K., Soutar, A.K. and Owen, J.S. Localization of apolipoprotein E receptor 2 to caveolae in the plasma membrane. J Lipid Res 2001, 42(6): 998-1002.
69. Ness, G.C., Kohlruss, N. and Gertz, K.R. Association of the low-density lipoprotein receptor with caveolae in hamster and rat liver. Biochem Biophys Res Comm 2003, 303(1): 177-81.
70. Fisher, T.S., Lo Surdo, P., Pandit, S. et al. Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. J Biol Chem 2007, 282(28): 20502-12.
71. LaRosa, J.C., He, J. and Vupputuri, S. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA 1999, 282(24): 2340-6.
72. Pignone, M., Phillips, C. and Mulrow, C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ 2000, 321(7267): 983-6.
73. Gould, A.L., Rossouw, J.E., Santanello, N.C., Heyse, J.F. and Furberg, C.D. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998, 97(10): 946-52.
74. Law, M.R., Wald, N.J. and Rudnicka, A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. BMJ 2003, 326(7404): 1423.
75. Chong, P. and Bachenheimer, B. Current, New and Future Treatments in Dyslipidaemia and Atherosclerosis. Drugs 2000, 60(1): 55-93.
76. Vaughan, C. and Gotto, A. Update on statins: 2003. Circulation 2004, 110(7): 886-92.
77. Vermes, A. and Vermes, I. Genetic polymorphisms in cytochrome P450 enzymes: Effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am J Cardiovasc Drugs 2004, 4(4): 247-55.
78. Evans, M., Roberts, A., Davies, S. and Rees, A. Medical lipid regulating therapy: Current evidence, ongoing trials and future developments. Drugs 2004, 64(11): 1181-96.
79. Lopez, D., Chambers, C.M., Keller, R.K. and Ness, G.C. Compensatory responses to inhibition of hepatic squalene synthase. Arch Biochem Biophys 1998, 351(2): 159-66.
80. Ness, G.C., Zhao, Z. and Lopez, D. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation. Arch Biochem Biophys 1996, 325(2): 242-8.
81. Mayne, J., Dewpura, T., Raymond, A. et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis 2008, 7: 22.
82. Rashid, S., Curtis, D.E., Garuti, R. et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A 2005, 102(15): 5374-9.
83. Graham, M.J., Lemonidis, K.M., Whipple, C.P., Subramaniam, A., Monia, B.P., Crooke, S.T. and Crooke, R.M. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res 2007, 48(4): 763-7.
84. Pandit, S., Wisniewski, D., Santoro, J.C. et al. Functional analysis of sites within PCSK9 responsible for hypercholesterolemia. J Lipid Res 2008, 49(6): 1333-43.